Portuguese Oncology Institute of Porto (IPO Porto)

Address Rua Dr. António Bernardino de Almeida,
4200-072
Porto, Portugal
Platforms ATMP & Biological, Biomarkers

The Portuguese Oncology Institute of Porto (IPO Porto) is a highly differentiated organisation belonging to the National Health System and providing specialised care. IPO Porto is a national and international reference health institution in oncological treatment, research and education. With open doors since 1974, it is the leading institution in treating patients with cancer and precancerous lesions, and this excellence in patient care is rooted in strong enforcement in research. IPO Porto admits about 10.000 new patients per year, currently providing healthcare to more than 45.000 patients. With the cancer patient as the main focus of all the organisational effort, it has the largest Bone Marrow Transplants unit and the largest Radio-oncology/Radiosurgery unit in Southwest Europe. In 2019, IPO Porto was certified by Gilead for implementing treatment with CAR-T cells under an early access program.

The Research Centre of IPO Porto (CI-IPOP) is the research branch of the Institute, having as main objective to understand the pathobiological mechanisms of cancer that may enable prevention, early diagnosis, correct evaluation of the prognosis and the development of more effective therapies. Officially established in September 2003, CI-IPOP was formally recognised by the Portuguese Science and Technology Foundation (FCT), the governmental agency that manages scientific and technological activities in Portugal, as an R&D Unit in 2004 and it was classified as ‘Excellent’ in its last external evaluation (2019). Currently, the Research Centre hosts 116 researchers, of whom about half are human resources from the IPO Porto, 20 are foreign-funded scholarship holders, 32 are registered doctoral students and 26 are researchers with doctor degree (including eight MDs). It includes seven research groups working on translational cancer research, five of which have a high-intensity laboratory level (Medical Physics, Radiobiology & Radiation Protection; Pathology & Experimental Therapy; Molecular Oncology & Viral Pathology; Cancer Epigenetics & Biology; Oncogenetics), and two that have been recently created to meet the growing needs on epidemiology of cancer, patient outcome and quality of life, as well as value-based healthcare and sustainability (Cancer Epidemiology Group and Management, Outcomes Research and Economics in Healthcare Group). CI-IPOP also hosts the Clinical Research Unit (which has Early Phase Clinical Trial division) and several clinical staff that publishes on a regular basis, which are not affiliated with any of the aforementioned research groups.

Contact

Facility Department of Genetics
Head of the facility

Expertise

Technologies
  • SangerSequencing
  • NGS-Whole genome sequencing (WGS)
  • NGS-Exome sequencing(WES)
  • NGS-other
  • Fluorescence in situ hybridization (FISH)
  • Multiplex ligation-dependent probe amplification (MLPA)
  • Genotyping
  • qPCR
  • Droplet Digital PCR (ddPCR)
  • Genome editing - CRISP/cas9
Purposes
  • Research
  • Clinical use
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Disease processes research

Features

Collaboration with industry where the institute collaborated with Genomics expertise (in the last 5 years) <10

Track record

Key opinion leaders
  • Manuel Teixeira

Expertise

Technologies
  • RT-PCR
  • Microarrays
Purposes
  • Research
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Non coding RNA analysis (miRNA, lncRNA, sRNA..)

Track record

Key opinion leaders
  • Carmen Jerónimo

Expertise

Technologies
  • DNA Methylation Analysis - High resolution melt (HRM)
  • ChIP (including ChIP-chip, ChIP-seq)
  • multiplex qMSP
Purposes
  • Research
  • Clinical use
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling

Features

Collaboration with industry where the institute collaborated with Epigenomics expertise (in the last 5 years) <10

Expertise

Technologies
  • Western Blot
  • ELISA
Purposes
  • Research
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Expression proteomics
  • Post-translational modifications

Track record

Key opinion leaders
  • Lúcio Lara Santos

DATA ANALYSIS for

  • Genomics
  • Proteomics
  • Metabolomics

DATA INTERPRETATION for

  • Genomics

STATISTICS

  • Molecular profiling (omics and others)
  • Expertise in clinical design of experiments, clinical statistics
  • Metadata (patient/sample information)

BIOINFORMATICS

  • Methylation profiling with array-types
  • Genetic analysis for Structural variation detection (Genome, Exome)
  • Informatics methods to support clinical decisions (diagnostic, predictive tests)

OMICS INTEGRATION METHODS

  • Published tools

Get in touch

Emanuela Oldoni

Share

Like what you read? Share your thoughts!